Doms № 1 -2022

Doms № 2 -2022 (40-50 p)

Switching from neutral protamine hagedorn insulin to insulin glargine 300 u/ml improves glycaemic control and reduces hypoglycaemia risk: results of a multicentre, prospective, observational study
Wolnik, D. Wiza, T. Szczepanik, A. Syta, T. Klupa


Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality worldwide and is an important public health issue. A significant proportion of insulin-treated patients with T2DM do not reach target glycated haemoglobin (HbA1c) values, which ultimately increases their risk of long-term microvascular and macrovascular complications. One potential option to improve diabetes control in these patients may be the use of new insulin formulations including second-generation basal insulin analogues such as insulin glargine 300 U/mL (Gla-300). Several published randomised controlled trials have assessed the clinical effectiveness of Gla-300, mostly versus insulin glargine 100 U/mL as well as insulin degludec. However, there is limited information about the real-world effectiveness of Gla-300 when patients are transitioned directly from neutral protamine Hagedorn (NPH) human basal insulin. The primary objective of this study was to evaluate the effectiveness of Gla-300, defined as the percentage of participants with an HbA1c reduction of ≥0.5%, 6 months after switching from NPH insulin, in participants with T2DM. Secondary objectives included the safety assessment based on the percentage of patients experiencing ≥1 episodes and the number of hypoglycaemic episodes by category: severe, symptomatic, symptomatic confirmed, diurnal or nocturnal, change in body weight, and insulin dose. A total of 469 participants completed the 6-month observation period. Mean baseline HbA1c was 9.19%. The percentage of participants with a ≥0.5% improvement in HbA1c from baseline was 71.7% at 6 months. Mean HbA1c decreased at 3 and 6 months by 0.77% (±0.98) and 1.01% (±1.12), respectively (p < 0.00001 versus baseline), while fasting glycaemia decreased by 32 mg/dL and 37 mg/dL, respectively (p < 0.00001 versus baseline). There were moderate increases in the doses of both Gla-300 and, if used, short-acting insulins during the 6 months of observation. The percentage of participants with ≥1 hypoglycaemia event during the preceding 4 weeks decreased significantly from baseline to 3 and 6 months, as did the proportion with symptomatic hypoglycaemia at night (p < 0.00001 versus baseline). No participants had severe hypoglycaemia after a switch to Gla-300. Body mass, waist and hip circumferences, and waist:hip ratio did not change significantly. In conclusion, this large, prospective, observational study demonstrated that switching from NPH insulin to Gla-300 resulted in a significant improvement in HbA1c, with only a moderate increase in insulin dose, a decreased risk of hypoglycaemia, and no increase in body weight.

Keywords: diabetes mellitus, type 2 doiabetus mellitus, hypoglycaeia, complications, basal insulin analogues

  1. R. Seaquist, J. Anderson, B. Childs et al., “Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society,” Diabetes Care, vol. 36, no. 5, pp. 1384-1395, 2013.
  2. Kunt and F. J. Snoek, “Barriers to insulin initiation and intensification and how to overcome them,” International Journal of Clinical Practice, vol. 63, pp. 6-10, 2009.3.
    P. E. Cryer, S. N. Davis, and H. Shamoon, “Hypoglycemia in diabetes,” Diabetes Care, vol. 26, no. 6, pp. 1902-1912, 2003.
  3. Bohn, W. Kerner, J. Seufert et al., “Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria,” Diabetes Research and Clinical Practice, vol. 115, pp. 31-38, 2016.
  4. M. Bala, E. Placzkiewicz-Jankowska, W. Lesniak et al., “Leczenie i spelnianie celów leczenia u polskich chorych na cukrzycç typu 2 od ponad 10 lat – wyniki badania ARE- TAEUS2-Grupa,” Endokrynologia Polska, vol. 65, no. 3, pp. 158-168, 2014.
  5. C. Cowie, “Diabetes diagnosis and control: missed opportunities to improve health: the 2018 Kelly West Award Lecture,” Diabetes Care, vol. 42, no. 6, pp. 994-1004, 2019.
  6. J. Lipska, X. Yao,J. Herrinet al., “Trendsindrug utilization, glycemic control, and rates of severe hypoglyce- mia, 20062013,” Diabetes Care, vol. 40, no. 4, pp. 468-475, 2017.
  7. Leiter, J. Yale, J. Chiasson, S. Harris, P. Kleinstiver, and L. Sauriol, “Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management,” Diabetes, vol. 29, pp. 186-192, 2005.
  8. Rys, P. Wojciechowski, A. Rogoz-Sitek et al., “Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus,” Acta Diabetologica, vol. 52, no. 4, pp. 649-662, 2015.
  9. Goldman and J. R. White Jr., “New insulin glargine 300 U/mL forthe treatment of type 1 and type2 diabetes mellitus,” The Annals of Pharmacotherapy, vol. 49, no. 10, pp. 1153-1161, 2015.
  10. Ritzel, R. Roussel, A. Giaccari, J. Vora,C. Brulle-Wohlhueter, and H. Yki-Järvinen, “Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 1 00 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes,”Diabetes,Obesity&Metabolism, vol. 20, no. 3, pp. 541-548, 2018.
  11. Seufert, A. Fritsche, H. Anderten, K. Pegelow, S. Pscherer, and M. Pfohl, Switching to Insulin Glargine 300 U/mL (Gla- 300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes (T2DM)
  12. on Basal Insulin Supported Oral Therapy, vol. 67, 78th Scientific Sessions of American Diabetes Association, 2018, (Poster 1020-P).
  13. Gupta, H. Wang, N. Skolnik et al., “Treatment dosing patterns and clinical outcomes for patients with type 2 diabetes starting or switching to treatment with insulin glargine (300 units per milliliter) in a real-world setting: a retrospective observational study,” Advances in Therapy, vol. 35, no. 1, pp. 43-55, 2018.
  14. Hidvegi and P. Stella, Effectiveness of Insulin Glargine 300 U/mL Used as a Part of Basal Bolus Therapy in People with T2DM-TOUJEO 6M. Real World Data from Hungary, 78th Scientific Sessions of American Diabetes Association, 2018, (Poster 1049-P).
  15. Freemantle, E. Chou, C. Frois et al., “Safety and efficacy of insulin glargine 300 U/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis,” BMJ Open, vol. 6, no. 2, article e009421, 2016.
  16. C. Riddle, G. B. Bolli, M. Ziemen, I. Muehlen-Bartmer, F. Bizet, and P. D. Home, “New insulin glargine 300 units/ mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1),” Diabetes Care, vol. 37, no. 10, pp. 2755-2762, 2014.
  17. Pettus, R. Roussel, F. L. Zhou et al., “Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U/mL versus first and second-generation basal insulin analogs: the real-world LIGHTNING study,” Diabetes Therapy, vol. 10, no. 2, pp. 617-633, 2019.